Pressure off Teva's CNS hopes as tardive dyskinesia drug succeeds
This article was originally published in Scrip
Executive Summary
Teva's investigational drug SD-809 (deutetrabenazine) has hit its endpoint in moderate to severe tardive dyskinesia patients in a pivotal Phase II/III trial, top-line results show. The drug, which Teva acquired when it bought Auspex Pharmaceuticals earlier this year, is one of the leading candidates in this neurological disease, for which there are currently no approved treatments in the US.
You may also be interested in...
10 Approvals To Watch For In Early 2017
Dupixent, Austedo, brigatinib and Olumiant are among a raft of new drug approvals expected in the first four months of the year. Here, with help from Informa Pharma's Biomedtracker, we take a look at 10 of the more interesting products looking close to reaching the market, some for the second time of asking.
Teva Preps For SD-809 Tardive Dyskinesia Filing By The End Of 2016
A second Phase III study testing the VMAT2 inhibitor in the indication was positive, positioning Teva for a neck-and-neck race to market against Neurocrine.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.